Live Breaking News & Updates on Elpiscience biopharma

Stay updated with breaking news from Elpiscience biopharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Compass Therapeutics, Inc (CMPX) Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models

Compass Therapeutics, Inc (CMPX) Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San-diego , California , United-states , China , San-diego-convention-center , American , Thomas-schuetz , Nasdaq , Handok-inc , Elpiscience-biopharma-ltd , Research-development-at-compass , American-association-for-cancer-research

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San-diego , California , United-states , China , Boston , Massachusetts , San-diego-convention-center , American , Thomas-schuetz , Danna-gifford , Exchange-commission , Handok-inc

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Major Histocompatibility Complex Class I negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of the fundamental recognition of. ....

California , United-states , China , Boston , Massachusetts , San-diego-convention-center , San-diego , American , Thomas-schuetz , Danna-gifford , Senior-communications , American-association-for-cancer-research

Christmas deal spree: See what J&J, Roche had in their stockings

Christmas deal spree: See what J&J, Roche had in their stockings
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Switzerland , Shanghai , China , Madrid , Spain , Swiss , John-orwin , Astellas-pharma , Elpiscience-biopharma , Amgen , Johnson , Health-science

Elpiscience out-licenses preclinical bispecific macrophage engagers to Astellas in deal worth up to $1.7B

Elpiscience Biopharma Ltd. is out-licensing to Astellas Pharma Inc. two preclinical bispecific macrophage engagers – ES-019, an anti-PD-L1/SIRPα bispecific antibody, and another unnamed program – in a deal worth up to $1.7 billion. The deal marks the Shanghai-based company’s first out-licensing deal, Elpiscience CEO Darren Ji told BioWorld, noting that Astellas will have global rights to both molecules with a potential to in-license two more. ....

Shanghai , China , Darren-ji , Astellas-pharma-inc , Elpiscience-biopharma-ltd , Elpiscience-biopharma , Astellas-pharma , Astellas-pharma-inc , Elpiscience-biopharma-ltd , Bispecific-macrophage-engagers , Es-019 , Abime